Novartis

Novartis

Web: Novartis external link
Location: Basel
Discipline: Medicine/Pharmacology
Related to:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
#display_name

Medicine Sep 23
Ilaris (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease -   These three simultaneous approvals conducted under FDA Priority Review follow Breakthrough Therapy Designations to address the unmet need of patients -   Ilaris provides rapid, sustained and complete disease control
Medicine Sep 23

In a Phase III clinical study, Zykadia extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance  -   Novartis is moving forward with global regulator

Medicine Sep 19

Important new analysis shows that Novartis' Entresto is associated with higher relative health-related quality of life scores among HFrEF patients New analysis of PARADIGM-HF data shows that among

Medicine Sep 16

ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya (fingolimod) had significantly lower disability progression compared to those w

Medicine Sep 22

Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites -   KA

Medicine Sep 17

EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary progre

Medicine Sep 15

Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries -   Retrospective tracing



website preview

Link

Medicine and Life Sciences